Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · IEX Real-Time Price · USD
1.760
-0.140 (-7.37%)
At close: Jul 2, 2024, 4:00 PM
1.750
-0.010 (-0.57%)
After-hours: Jul 2, 2024, 7:42 PM EDT
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RGLS stock have an average target of 11, with a low estimate of 3.00 and a high estimate of 28. The average target predicts an increase of 525.00% from the current stock price of 1.76.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RGLS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $28 | Strong Buy | Maintains | $11 → $28 | +1,490.91% | Jun 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +468.18% | Jun 25, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +354.55% | May 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +411.36% | May 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +411.36% | May 6, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.63
from -1.58
EPS Next Year
-0.76
from -0.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 185.6M | 673.3M |
| Avg | n/a | n/a | n/a | 90.2M | 339.3M |
| Low | n/a | n/a | n/a | n/a | 23.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 646.7% |
| Avg | - | - | - | - | 276.2% |
| Low | - | - | - | - | -73.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.60 | -0.70 | -0.71 | 0.95 | 4.82 |
| Avg | -0.63 | -0.76 | -0.82 | 0.92 | 4.68 |
| Low | -0.63 | -0.79 | -0.89 | 0.88 | 4.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 425.0% |
| Avg | - | - | - | - | 410.0% |
| Low | - | - | - | - | 390.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.